Venus Remedies Limited
Venus Remedies Limited (VENUSREM) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
venusremedies.com(opens the company website in a new tab)Key metrics
Price as of 2026-09-02
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 168 Cr | 143 Cr | 195 Cr | 109 Cr | 167 Cr | 177 Cr | 195 Cr | 132 Cr | 193 Cr | 180 Cr | 259 Cr | 179 Cr |
| Operating expenses (approx.) | 150 Cr | 131 Cr | 176 Cr | 97 Cr | 163 Cr | 159 Cr | 166 Cr | 122 Cr | 162 Cr | 143 Cr | 196 Cr | 145 Cr |
| EBITDA | 18 Cr | 12 Cr | 19 Cr | 11 Cr | 5 Cr | 18 Cr | 29 Cr | 10 Cr | 31 Cr | 38 Cr | 63 Cr | 34 Cr |
| OPM % | 10.6% | 8.4% | 10.0% | 10.4% | 2.9% | 10.4% | 14.9% | 7.7% | 16.1% | 20.8% | 24.4% | 19.1% |
| Other income | 3 Cr | 2 Cr | 4 Cr | 2 Cr | 11 Cr | 2 Cr | 7 Cr | 9 Cr | 2 Cr | 3 Cr | 5 Cr | 3 Cr |
| Interest | 0.06 Cr | 0.07 Cr | 0.02 Cr | 0.02 Cr | 0.02 Cr | 0.01 Cr | 0.01 Cr | 0.01 Cr | 0.01 Cr | 0.01 Cr | 0.01 Cr | 0 Cr |
| Depreciation | 6 Cr | 7 Cr | 6 Cr | 6 Cr | 6 Cr | 5 Cr | 5 Cr | 6 Cr | 6 Cr | 7 Cr | 7 Cr | 7 Cr |
| Profit before tax | 14 Cr | 8 Cr | 17 Cr | 7 Cr | 9 Cr | 25 Cr | 28 Cr | 13 Cr | 26 Cr | 33 Cr | 62 Cr | 30 Cr |
| Tax % | 30.7% | 12.0% | 39.9% | 82.2% | 61.3% | 21.2% | 25.3% | 23.9% | 24.0% | 23.6% | 22.9% | 23.5% |
| Net profit | 10 Cr | 7 Cr | 11 Cr | 1 Cr | 4 Cr | 20 Cr | 21 Cr | 10 Cr | 20 Cr | 26 Cr | 47 Cr | 23 Cr |
| EPS (₹) | ₹7.44 | ₹5.13 | ₹7.86 | ₹0.92 | ₹2.63 | ₹14.66 | ₹15.71 | ₹7.18 | ₹15.06 | ₹19.14 | ₹35.53 | ₹17.18 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 341 Cr | 548 Cr | 599 Cr | 556 Cr | 601 Cr | 648 Cr | 770 Cr | Sign in for TTM |
| Operating expenses (approx.) | 301 Cr | 494 Cr | 537 Cr | 495 Cr | 542 Cr | 584 Cr | 622 Cr | Sign in for TTM |
| EBITDA | 41 Cr | 54 Cr | 62 Cr | 60 Cr | 60 Cr | 64 Cr | 147 Cr | Sign in for TTM |
| OPM % | 12.0% | 9.8% | 10.4% | 10.8% | 9.9% | 9.8% | 19.1% | Sign in for TTM |
| Other income | 5 Cr | 20 Cr | 8 Cr | 10 Cr | 12 Cr | 21 Cr | 13 Cr | Sign in for TTM |
| Interest | 13 Cr | 13 Cr | 0.48 Cr | 0.29 Cr | 0.09 Cr | 0.07 Cr | 0.04 Cr | Sign in for TTM |
| Depreciation | 32 Cr | 35 Cr | 34 Cr | 32 Cr | 26 Cr | 23 Cr | 26 Cr | Sign in for TTM |
| Profit before tax | -8 Cr | 49 Cr | 36 Cr | 38 Cr | 45 Cr | 69 Cr | 134 Cr | Sign in for TTM |
| Tax % | -24.4% | -27.2% | -11.9% | 29.9% | 36.2% | 34.2% | 23.4% | Sign in for TTM |
| Net profit | -10 Cr | 62 Cr | 41 Cr | 27 Cr | 28 Cr | 45 Cr | 103 Cr | Sign in for TTM |
| EPS (₹) | ₹-8.10 | ₹50.04 | ₹30.86 | ₹19.88 | ₹21.31 | ₹33.90 | ₹76.89 | Sign in for TTM |
| Dividend payout % | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity capital | 12 Cr | 12 Cr | 13 Cr | 13 Cr | 13 Cr | 13 Cr | 13 Cr |
| Reserves | 311 Cr | 388 Cr | 427 Cr | 447 Cr | 474 Cr | 548 Cr | 650 Cr |
| Borrowings | — | — | — | 42 Cr | 41 Cr | 2 Cr | — |
| Other liabilities | — | — | — | 98 Cr | 98 Cr | 153 Cr | 190 Cr |
| Total liabilities | — | — | — | 601 Cr | 627 Cr | 716 Cr | 854 Cr |
| Fixed assets (net) | — | — | — | 137 Cr | 133 Cr | 125 Cr | 125 Cr |
| CWIP | — | — | — | 26 Cr | 21 Cr | 26 Cr | 51 Cr |
| Investments | — | — | — | 20 Cr | 19 Cr | 84 Cr | 238 Cr |
| Inventories | — | — | — | 120 Cr | 122 Cr | 100 Cr | 129 Cr |
| Trade receivables | — | — | — | 77 Cr | 81 Cr | 112 Cr | 103 Cr |
| Cash & bank | — | — | — | 21 Cr | 49 Cr | 58 Cr | 25 Cr |
| Other assets | — | — | — | 200 Cr | 202 Cr | 210 Cr | 182 Cr |
| Total assets | — | — | — | 601 Cr | 627 Cr | 716 Cr | 854 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | 41 Cr | 37 Cr | 37 Cr | 86 Cr | 156 Cr |
| Cash from investing | — | — | -17 Cr | -51 Cr | -7 Cr | -76 Cr | -182 Cr |
| Cash from financing | — | — | -9 Cr | -0.57 Cr | -1 Cr | -1 Cr | -3 Cr |
| Net cash flow | — | — | 14 Cr | -22 Cr | 28 Cr | 9 Cr | -32 Cr |
| Free cash flow (OCF − Capex) | — | — | 27 Cr | 29 Cr | 24 Cr | 68 Cr | 118 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| ROCE % | 1.6% | 15.4% | 8.4% | 7.6% | 8.5% | 12.3% | 20.2% |
| ROE % | 0.0% | 0.0% | 0.0% | 0.0% | 5.6% | 8.1% | 0.0% |
| Debtor days | — | — | — | 50 | 49 | 63 | 49 |
| Inventory days | — | — | — | 137 | 129 | 105 | 121 |
| Days payable | — | — | — | 58 | 47 | 96 | 106 |
| Cash conversion cycle | — | — | — | 129 | 131 | 72 | 64 |
| Debt / equity | — | — | — | 0.09 | 0.08 | 0.0030 | — |
| Current ratio | — | — | — | 3.91 | 4.53 | 3.31 | 2.44 |
| Net debt / EBITDA | 0.00 | 0.00 | 0.00 | 0.35 | -0.13 | -0.88 | -0.17 |
Compare with peers
Loading peers…